| Title | Value of anti-infective chemoprophylaxis in primary systemic vasculitis: what is the evidence? | | Author(s) | Moosig F, Holle JU, Gross WL | | Institution | Department of Rheumatology, University Hospital of Schleswig Holstein and Klinikum Bad Bramstedt, Oskar Alexander Str, 26, 24576 Bad Bramstedt, Germany. moosig@klinikumbb.de. | | Source | Arthritis Res Ther 2009 Oct 28; 11(5):253. | | Abstract | ABSTRACT: Although infections are a major concern in patients with primary systemic vasculitis, actual knowledge about risk factors and evidence concerning the use of anti-infective prophylaxis from clinical trials are scarce. The use of high dose glucocorticoids and cyclophosphamide pose a definite risk for infections. Bacterial infections are among the most frequent causes of death, with Staphylococcus aureus being the most common isolate. Concerning viral infections, cytomegalovirus and varicella-zoster virus reactivation represent the most frequent complications. The only prophylactic measure that is widely accepted is trimethoprim/sulfamethoxazole to avoid Pneumocystis jiroveci pneumonia in small vessel vasculitis patients with generalised disease receiving therapy for induction of remission. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19886977 |
|
